An2 Therapeutics Inc (ANTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -17,775 | -7,655 | -21,543 | -13,998 | -7,055 |
| Depreciation Amortization | -72 | 1 | 53 | 30 | 11 |
| Accounts payable and accrued liabilities | 1,987 | 1,546 | 417 | 1,363 | 652 |
| Other Working Capital | -218 | 445 | 32 | 1,936 | 57 |
| Other Operating Activity | -259 | -1,079 | 557 | -822 | -465 |
| Operating Cash Flow | $-16,337 | $-6,742 | $-20,484 | $-11,491 | $-6,800 |
| Cash Flows From Investing Activities | |||||
| Purchase Of Investment | -53,984 | -998 | -77,274 | -61,270 | -49,284 |
| Sale Of Investment | 28,475 | 14,975 | 27,250 | 5,000 | N/A |
| Investing Cash Flow | $-25,509 | $13,977 | $-50,024 | $-56,270 | $-49,284 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 70,365 | 63,198 | 11 | 10 | 10 |
| Common Stock Repurchased | N/A | -11 | N/A | N/A | N/A |
| Other Financing Activity | 0 | 0 | 78,524 | 79,494 | 79,734 |
| Financing Cash Flow | $70,365 | $63,187 | $78,535 | $79,504 | $79,744 |
| Beginning Cash Position | 12,097 | 12,097 | 4,070 | 4,070 | 4,070 |
| End Cash Position | 40,616 | 82,519 | 12,097 | 15,813 | 27,730 |
| Net Cash Flow | $28,519 | $70,422 | $8,027 | $11,743 | $23,660 |
| Free Cash Flow | |||||
| Operating Cash Flow | -16,337 | -6,742 | -20,484 | -11,491 | -6,800 |
| Free Cash Flow | -16,337 | -6,742 | -20,484 | -11,491 | -6,800 |